After Travere Therapeutics (TVTX) announced that the FDA informed the company it no longer plans to hold an advisory committee meeting to review the sNDA for Filspari for focal segmental glomerulosclerosis, Jefferies analyst Maury Raycroft believes the AdCom cancellation is “a clear positive” that suggests that FDA is fully on board with using UPCR as a surrogate end point for full approval. Noting that management remains confident in getting Filsapri approved for FSGS by the PDUFA date of January 13, the firm adds that it thinks approval could come in earlier and reiterates its $35 price target and Buy rating heading into what it sees as a “likely approval.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- FDA reversing course on adcomm should reassure Travere investors, says BofA
- FDA Drops Advisory Committee for Travere’s FILSPARI Review
- FDA says advisory committee no longer needed for Travere Filspari sNDA
- Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
- Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz